229 related articles for article (PubMed ID: 15051550)
1. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
Goldie SJ; Kim JJ; Wright TC
Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
Kim JJ; Wright TC; Goldie SJ
JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
[TBL] [Abstract][Full Text] [Related]
3. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
[TBL] [Abstract][Full Text] [Related]
4. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ; Wright TC; Goldie SJ
J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Québec, Canada.
Vijayaraghavan A; Efrusy MB; Mayrand MH; Santas CC; Goggin P
Can J Public Health; 2010; 101(3):220-5. PubMed ID: 20737813
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
9. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
10. Benefits and costs of using HPV testing to screen for cervical cancer.
Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cervical cancer screening: cytology versus human papillomavirus DNA testing.
van Rosmalen J; de Kok IM; van Ballegooijen M
BJOG; 2012 May; 119(6):699-709. PubMed ID: 22251259
[TBL] [Abstract][Full Text] [Related]
12. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
[TBL] [Abstract][Full Text] [Related]
13. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness.
Goldie SJ; Kuhn L; Denny L; Pollack A; Wright TC
JAMA; 2001 Jun; 285(24):3107-15. PubMed ID: 11427139
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness analysis of HPV primary screening and dual stain cytology triage compared with cervical cytology.
Termrungruanglert W; Khemapech N; Tantitamit T; Havanond P
J Gynecol Oncol; 2019 Mar; 30(2):e17. PubMed ID: 30740950
[TBL] [Abstract][Full Text] [Related]
15. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
Vassilakos P; Poncet A; Catarino R; Viviano M; Petignat P; Combescure C
Gynecol Oncol; 2019 Apr; 153(1):92-99. PubMed ID: 30718124
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.
Vijayaraghavan A; Efrusy MB; Goodman KA; Santas CC; Huh WK
Gynecol Oncol; 2010 Nov; 119(2):237-42. PubMed ID: 20713299
[TBL] [Abstract][Full Text] [Related]
19. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]